Among all the reported non-peptidomimetic small inhibitors, 5-hydroxy-9,10-dioxo-9,10-dihydroanthracene-1-sulfonamide (LLL12) has the lowest IC50 (0.16−3.09 μM), inhibiting STAT3 phosphorylation and the growth of human cancer cells [17]. The gene discussed is STAT3; the disease is cancer.